Medical technology growth company Injeq Oy is planning an IPO and listing on the First North marketplace

Injeq Oy

Press release 21 February 2022 at 8.30 am

NOT TO BE PUBLISHED OR DISSEMINATED, WHOLLY OR PARTIALLY, DIRECTLY OR INDIRECTLY IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE OR SOUTH AFRICA OR IN THESE COUNTRIES OR IN ANY OTHER COUNTRY WHERE PUBLICATION OR DISSEMINATION WOULD BE UNLAWFUL.

Injeq Oy (“Injeq”, the “Company”), a Finnish medical technology growth company, is planning an IPO (“IPO”) and listing (“Listing”) on the First North Growth Market Finland (“First North”) marketplace maintained by Nasdaq Helsinki Oy during 2022. The funds raised in the planned IPO will be used to implement the Company’s commercialization and growth strategy. The planned IPO would consist exclusively of new shares issued by the Company. None of Injeq’s current owners will sell their shares in connection with the IPO.

Injeq is a medical technology company in the early stages of commercial expansion with a mission to produce intelligent medical solutions for demanding patient injections. The company received the approval of the first notified body (TÜV SÜD Product Service GmbH) (CE certification) for its first product, the IQ-Tip® smart needle, in December 2021. With the CE certification in accordance with the MDR, the marketing of the company’s IQ-Tip® smart needle and sales have started in Europe. The company has already agreed on sales channels through distributors in Finland, Germany, Scandinavia, Italy, Austria, France, Slovenia and Switzerland, in addition to which the company is negotiating in several other European countries, including Spain, the Netherlands, the United Kingdom and Poland.

In the core of Injeq’s growth strategy is the European market, in addition to which the Company intends to expand into new application areas and global markets in the future, such as the United States and selected Asian countries.

The prevalent practice of lumbar puncture, is more than 100 years old and is based almost exclusively on the finger sensory of the doctor performing the procedure, making the risk of puncture failure relatively high. The IQ-Tip® smart needle allows demanding patient injections to be performed safely. Developed at the initiative of physicians, the IQ-Tip® smart needle facilitates doctors’ work while improving patient safety and treatment effectiveness. The IQ-Tip® smart needle is suitable for lumbar puncture from neonates to the elderly, including punctures of spinal cavity in children with leukemia. The IQ-Tip® smart needle is the result of long product development and several clinical patient studies. Injeq’s technology is scalable and can be extended to other applications that require patient injections.

Injeq’s Chairman of the Board Tommi Rasila comments: “Demanding patient injections are increasing worldwide and there is a real need in the market to improve patient safety and facilitate doctors’ work. Our vision of the smart needle has progressed to a complete product and with the CE certification we have moved into commercial operations. Our product utilizes patented technology, and to the best of our knowledge, there is no product on the market with similar features. The technology we have developed is scalable and expandable to other similar demanding applications, such as multiple patient injection and biopsy applications, providing our Company with significant future growth potential.”

Founded in 2010, Injeq operates in Tampere and employs almost 20 people. Injeq is backed by an experienced team of medical and medical technology experts as well as extensive scientific research. Timo Hänninen, D.Sc., MBA has been appointed the company’s President and CEO as of February 14, 2022.

Further information Injeq OyTommi Rasila, Chairman of the Boardtel. 040 750 8158tommi.rasila@injeq.com

Injeq in brief Injeq Oy is a Finnish growth company in innovative medical technology, whose mission is to produce technically intelligent solutions for medically demanding patient injections. Developed at the request of physicians, the IQ-Tip® smart needle facilitates physicians’ work to improve patient safety and treatment effectiveness. The IQ-Tip® smart needle is a modern way to perform demanding patient injections safely. The first stage is lumbar puncture, a clinical procedure in which the spinal fluid is sampled or a drug is administered into the spinal cavity. The clinical performance and safety of the product at lumbar punctures have been evaluated in three clinical trials in Finnish university hospitals. The smart needle is suitable for lumbar puncture from newborns to the elderly, one of the main uses being for the treatment of leukemia children. Founded in 2010, Injeq operates in Tampere and currently employs 19 people. Injeq is supported by an experienced team of medical experts and extensive scientific research. IQ-Tip® is a registered trademark of Injeq.

NOTICE OF THE ANNUAL GENERAL MEETING

Notice is given to the shareholders of Injeq Oyj of the Annual General Meeting to be held on 31 May […]
Read more »

Incidence of traumatic lumbar punctures in neonates and infants

The part two of the trilogy has now been published. This article of the three part series examines the incidence […]
Read more »

Injeq whipaper on lumbar puncture

Our whitepaper takes a closer look at the lumbar puncture, the IQ-Tip® system’s first indication, and presents the results that […]
Read more »

Bioimpedance spinal needle provides high success and low complication rate in lumbar punctures of pediatric patients with acute lymphoblastic leukemia

The great results of our latest clinical investigation have now been published as an open access article in Scientific Reports, […]
Read more »

Injeq Oy Shares Have Been Transferred to Finnish Book-Entry Securities System – Instructions for Shareholders

Injeq Oy Annual General Meeting resolved on 26th May 2021 to transfer the shares of the company into the Finnish […]
Read more »

Traumatic lumbar punctures in diagnostic and intrathecal treatment punctures of pediatric hemato-oncology patients

Extensive study of CSF laboratory analysis records by pediatricians and Injeq’s researchers has been published as an open access article […]
Read more »